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Summary
Many patients with primary immunodeficiency (PID) who have antibody
deficiency develop progressive lung disease due to underlying subclinical
infection and inflammation. To understand how these patients are
monitored we conducted a retrospective survey based on patient records of
13 PID centres across Europe, regarding the care of 1061 adult and 178
paediatric patients with PID on immunoglobulin (Ig) G replacement. The
most common diagnosis was common variable immunodeficiency in adults
(75%) and hypogammaglobulinaemia in children (39%). The frequency of
clinic visits varied both within and between centres: every 1–12 months for
adult patients and every 3–6 months for paediatric patients. Patients
diagnosed with lung diseases were more likely to receive pharmaceutical
therapies and received a wider range of therapies than patients without lung
disease. Variation existed between centres in the frequency with which some
clinical and laboratory monitoring tests are performed, including exercise
tests, laboratory testing for IgG subclass levels and specific antibodies, and
lung function tests such as spirometry. Some tests were carried out more
frequently in adults than in children, probably due to difficulties conducting
these tests in younger children. The percentage of patients seen regularly by
a chest physician, or who had microbiology tests performed following chest
and sinus exacerbations, also varied widely between centres. Our survey
revealed a great deal of variation across Europe in how frequently patients
with PID visit the clinic and how frequently some monitoring tests are
carried out. These results highlight the urgent need for consensus guidelines
on how to monitor lung complications in PID patients.
Keywords: antibody deficiency, lung disease, monitoring, primary immuno-
deficiency disease, subclinical infection
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Introduction
Approximately 70–75% of patients with primary immuno-
deficiency disease (PID) suffer from antibody deficiency [1].
Many of these patients may develop progressive lung disease
as a result of underlying subclinical infection and inflamma-
tion, despite apparently adequate levels of replacement
immunoglobulin (Ig)G [2–6]. Viral and bacterial pathogens
have been detected in secretions from the airways of patients
with PID with persistent and/or recurrent infections [7–11]
and from PID patients with no apparent infections at the
time of testing [7]. Consensus of a meeting of European
Union (EU) experts (Paris, June 2013) was that subclinical
infection is not monitored adequately, and wide variation
may exist between centres in the methods and frequency of
monitoring both for evidence of infection and development
of chronic lung disease.
Currently, a number of screening measures are used in
different centres to diagnose and monitor patients with
PID, including lung function tests such as forced expiratory
volume at 1 s (FEV1), forced vital capacity (FVC) and
transfer factor for carbon monoxide (TLCO); imaging
techniques such as high-resolution computerised tomogra-
phy (HRCT) and magnetic resonance imaging (MRI); and
numerous other tests, including cultures from induced
sputum, blood gas analysis and exercise testing. However,
the frequency with which these are applied is not standar-
dised, and there is currently a lack of local and national
guidelines for screening and treating lung disease in PID.
It is expected that differences may exist between the fre-
quency with which some clinical and laboratory monitoring
tests are performed in adult and paediatric patients, due to the
challenges of performing some of these tests in infants. For
instance, infants can require sedation or a general anaesthetic
in order for HRCT or MRI to be carried out [12,13]. In addi-
tion, lung function testing, TLCO in particular, can only be
performed reliably in children aged more than 6 years [14].
To understand more clearly the current practice in how
PID patients with antibody deficiency across Europe are
screened and monitored in both adult and paediatric
patients with different categories of lung disease, a survey
was conducted to identify screening tests and their timing
in different centres.
Methods
A survey exploring which screening protocols are used in the
assessment of PID was conducted from September to Novem-
ber 2015 (Supporting information). The survey included 12
questions and was e-mailed to 13 different centres in eight
European countries: Belgium, France, Germany, Italy, the
Netherlands, Spain, Sweden and the United Kingdom.
Information was requested on the number of paediatric
and adult patients with antibody deficiency for six patient
groups:
 Paediatric/adult PID patients with no apparent lung
disease
 Paediatric/adult PID patients with bronchiectasis
 Paediatric/adult PID patients with other lung disease,
e.g. fibrosing lung disease or granulomatous and lym-
phocytic interstitial lung disease (GLILD) (group
referred to as ‘other lung disease’)
Respondents were asked to consider only patients treated
with IgG replacement therapy. PIDs were defined according
to the European Society for Immunodeficiencies (ESID)
criteria. Common variable immunodeficiency (CVID) was
diagnosed according to the ESID/Pan-American Group for
Immunodeficiency (PAGID) criteria or revised ESID crite-
ria [15,16].
For each patient group described above, information
was requested on how frequently patients attended the
clinic for monitoring and assessment, which screening and
monitoring tests were used and how often and which treat-
ments were administered at their centre for patients with
PID.
Data on how many patients received different therapies
(in addition to IgG replacement therapy), including pro-
phylactic antibiotics, steroids and other therapies such as
rituximab, were collected. The proportion of patients
treated with each therapy was calculated as a percentage.
Survey respondents were asked to consider how fre-
quently they undertake different types of tests for ongoing
monitoring for each group of patients. Tests were divided
into five categories: clinical monitoring and assessment,
laboratory monitoring, lung function, imaging and other
monitoring tests. The frequency of testing was recorded as
(1) scheduled regularly or at the clinic visit, (2) as required
or (3) never. The proportion of patients included in each
frequency group was calculated as a percentage.
A Fisher’s exact test was conducted to assess whether
there were any statistically significant differences regarding
the frequency with which the clinical monitoring and
assessment tests were conducted between the different dis-
ease groups (without lung disease, with bronchiectasis or
with ‘other lung disease’) for either adult or paediatric
patients. Information about which guidelines were fol-
lowed for screening, treating and monitoring patients with
PID, the percentage of patients seen regularly by a chest
physician at their institute and the frequency of microbiol-
ogy testing in patients with chest and sinus exacerbations
was also collected.
Results
Patient characteristics
A total of 1239 patients with PID presenting with antibody
deficiency and receiving IgG treatment were included in
this survey (Table 1). The most common underlying PID
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diagnosis for paediatric patients was hypogammaglobuli-
naemia (39%), whereas the majority of adult patients had
been diagnosed with CVID (75%). Of the patients included
in the survey, 24% of children and 36% of adults had been
diagnosed with lung disease.
Patients diagnosed with lung diseases were more likely to
receive prophylactic antibiotics, steroids, rituximab or other
pharmacological treatments than patients without lung dis-
ease. A higher percentage of patients with bronchiectasis or
‘other lung disease’ received prophylactic antibiotics com-
pared to those without lung disease (Fig. 1). A higher per-
centage of clinicians treating paediatric patients reported
prescribing prophylactic antibiotics compared to those treat-
ing adult patients, regardless of the presence or type of lung
disease. The percentages of patients receiving prophylactic
antibiotics varied widely in all categories, as some respond-
ents stated that they treated all patients with antibiotic pro-
phylaxis, while others never recommended this therapy for
these patient categories. In addition, a higher percentage of
adult patients received inhaled and/or oral steroids than
paediatric patients, regardless of the presence or type of lung
diseases. Steroids (inhaled and/or oral) were given most
commonly to those with ‘other lung disease’ (65% of adult
patients and 57% of paediatric patients), followed by
patients with bronchiectasis (50% of adult patients and 32%
of paediatric patients), and given to 31% of adults and 0%
of paediatric patients without lung disease.
Frequency of clinic visits
There was a greater variation between centres in the fre-
quency of clinic visits for adults than paediatric patients.
Clinicians saw paediatric patients routinely every 3–6
months, whereas adult patients were seen from once every
month to once every 12 months. Variation also existed
within centres, with some clinicians seeing patients at fixed
intervals (commonly every 3 or 6 months for both adult
Table 1. Number of patients treated by participating physicians, with
diagnoses
Paediatric
patients
Adult
patients
Patients and centres
Number of centres treating
patients (n 5 13)
8 9
Total number of patients
treated (n 5 1239)
178 1061
Patients with and without lung disease, number of patients (%)
Without lung disease 133 (75) 539 (51)
With bronchiectasis 38 (21) 358 (34)
With ‘other lung disease’ 7 (4) 164 (15)
Diagnoses
Diagnoses for all patients, number of patients (%)
CVID 57 (32) 798 (75)
XLA 33 (19) 42 (4)
SPAD 13 (7) 37 (3)
ARAG 6 (3) 4 (0.4)
Hypogammaglobulinaemia 69 (39) 180 (17)
Diagnoses for patients with progressive lung disease,* number of
patients (%)
CVID 18 (42) 307 (80)
XLA 7 (16) 18 (5)
SPAD 2 (5) 9 (2)
ARAG 2 (4) 4 (1)
Hypogammaglobulinaemia 14 (33) 40 (12)
ARAG 5 autosomal recessive agammaglobulinaemia; CVID 5
common variable immune deficiency; SPAD 5 selective or partial
antibody deficiency; XLA 5 X-linked agammaglobulinaemia. *Lung
disease that worsens over time, including bronchiectasis and other
lung disease.
Fig. 1. Percentage of primary immunodeficiency (PID) patients
receiving prophylactic antibiotics, rituximab, steroids and other
treatments, (a) without lung disease, (b) with bronchiectasis, and (c)
with ‘other lung disease’. : Adult patients : Paediatric
patients.
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and paediatric patients) and others seeing patients based
on clinical findings; for example, one centre reviewed adult
patients every 4–12 months. Clinicians commented that
patients were seen more frequently if they were particularly
unwell; for example, patients with cancer, chronic lung dis-
ease or malabsorption may be seen every month. For
paediatric patients, respondents generally reported seeing
those with bronchiectasis or ‘other lung disease’ more fre-
quently than those with no lung disease (mean: 37, 37
and 52 months, respectively). For adult patients, respond-
ents generally reported seeing those with ‘other lung dis-
ease’ (such as fibrosing lung disease or GLILD) more
frequently than those with bronchiectasis and no lung dis-
ease (mean: 33, 47 and 49 months, respectively).
Clinical monitoring and assessment
The frequency with which clinical monitoring and assess-
ment was carried out was similar for adult and paediatric
patients for most tests, as shown in Fig. 2. In addition, no
significant differences were observed between the frequen-
cies of testing for patients without lung disease, with bron-
chiectasis or with ‘other lung disease’, for either adult or
paediatric patients. The majority of clinical monitoring was
performed regularly at clinic visits, where all respondents
conducted a clinical examination and recorded frequencies
of respiratory tract infection and sinusitis since the last
visit. For exercise tests, fatigue assessments and quality of
life assessments a particularly wide variation was seen in
the frequencies of testing at different centres (Fig. 2). Exer-
cise tests were performed less frequently in paediatric
patients than adult patients (25 versus 44–63%, respec-
tively), regardless of the presence of lung disease.
Laboratory monitoring tests
For patients without lung disease, the frequency of labora-
tory monitoring varied greatly between the different centres,
as did the tests used (Fig. 3). However, few differences in the
frequency of testing were seen in the monitoring of adult
compared to paediatric patients (Fig. 3). In addition, there
were no significant differences in the frequency of perform-
ing laboratory monitoring, including sputum analysis, viral
swabs and deep sequencing, for either adult or paediatric
patients with and without lung disease.
Testing for elastase in sputum and deep sequencing for
detecting pathogens were carried out by only a minority
(0–25%), regardless of the patient’s age or the presence of
lung disease. The frequency of testing for specific antibod-
ies and IgG2 and IgG3 trough levels varied widely between
centres. For all groups of patients at least 71% of clinicians
reported that IgG trough levels and IgA and IgM levels
Fig. 2. Frequency with which clinical monitoring tests are performed in patients with primary immunodeficiency (PID). : Performed at clinic
visit; : Performed as required; : Never performed. P 5 paediatric patients (eight centres); A 5 adult patients (nine centres).
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were assessed routinely at clinic visits; this was more
frequently than for monitoring IgG subclass levels,
which were assessed only routinely or as required by
approximately 50% of clinicians, regardless of age or the
presence of lung disease. Testing for specific antibodies was
conducted slightly more frequently by clinicians monitor-
ing adult patients compared to those monitoring paediatric
patients; depending on the presence of lung disease, these
tests were never performed by 38–50% of centres treating
children, compared to 22–25% of centres treating adults.
Swabs for viral polymerase chain reaction (PCR) testing
were carried out mainly as required, regardless of age or
lung disease. One respondent commented that obtaining
routine viral swabs for PCR testing was discontinued
recently at their institute following an audit, and is now
performed only when the patient is symptomatic.
Lung function tests
Lung function tests were carried out routinely at the major-
ity of centres. There were generally only small variations in
the frequency of testing between adult and paediatric
patients (Fig. 4) and no significant differences were observed
between different disease groups. However, there was a trend
towards more frequent testing in adult versus paediatric
patients with ‘other lung disease’. For example, FEV1 and
Fig. 3. Frequency with which laboratory monitoring tests are performed in patients with primary immunodeficiency (PID). : Performed at
clinic visit; : Performed as required; : Never performed. P 5 paediatric patients (eight centres); A 5 adult patients (nine centres); CRP 5 C-
reactive protein; PCR 5 polymerase chain reaction.
Fig. 4. Frequency with which lung function tests are performed in
patients with primary immunodeficiency (PID). : Performed at
clinic visit; : Performed as required; : Never performed.
P 5 paediatric patients (eight centres); A 5 adult patients (nine
centres). FEV1 5 forced expiratory volume at 1 s; FVC 5 forced
vital capacity; TLCO 5 transfer factor for carbon monoxide;
PEFR 5 peak expiratory flow rate; FEF 25–75 5 the forced
expiratory flow at 25–75% of FVC.
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FVC were performed at clinic visits in 50% of paediatric
patients with ‘other lung disease’ compared to 78% of
adults. Additionally, for both adult and paediatric patients,
lung function tests were generally performed more fre-
quently in patients with lung disease than without; for exam-
ple, FEV1, FVC, peak expiratory flow rate (PEFR) and the
forced expiratory flow at 25–75% of FVC (FEF 25–75) were
performed routinely at clinic visits by 50–63% of respond-
ents when treating adults with no lung disease, compared to
67–78% of respondents when treating adults with bron-
chiectasis or ‘other lung disease’. The same was true for the
frequency of lung function tests for paediatric patients with
no lung disease versus bronchiectasis. There was also no sig-
nificant difference in the frequency of testing for paediatric
patients without lung disease and those with ‘other lung dis-
ease’; however, this may be due to the low number of the lat-
ter patient category included in this survey (n5 10).
TLCO was performed routinely by fewer clinicians than
the other tests for both adult and paediatric patients. In
adults the test was performed at routine clinic visits by
38% of clinicians for patients without lung disease, 44%
for patients with bronchiectasis and 56% for patients with
‘other lung disease’. However, TLCO was performed less
routinely in paediatric patients; it was performed by only
13% of clinicians treating those with no lung disease or
bronchiectasis, and by 25% of clinicians when treating chil-
dren with ‘other lung disease’. In addition, TLCO was never
performed in paediatric patients by 25–38% of clinicians.
Imaging
Although no significant difference between disease groups
was observed, there was a trend for all imaging tests to be
carried out slightly more frequently in adult than paediatric
patients with no lung disease (Fig. 5). Additionally, HRCT
imaging was performed at least occasionally by all clini-
cians for paediatric patients with lung disease, whereas
25% never carried out the test in paediatric patients with-
out lung disease. For adult patients, approximately half of
all respondents performed HRCT imaging regularly and
the other half performed HRCT imaging as required,
regardless of the presence or type of lung disease. When
asked which imaging techniques were used to assess which
organs, HRCT was the predominant imaging modality
used for the lungs.
MRI was used by some respondents for imaging of the
brain and central nervous system; however, this was rarely
performed. In patients without lung disease, MRI was
never performed by 63% of clinicians treating paediatric
patients, and was performed as needed by the remainder
(Fig. 5). MRI was performed more frequently in adult
patients; it was performed routinely by 13% of clinicians
and as needed by approximately half of respondents. Only
minimal variations were seen in the frequency of MRI for
patients with and without lung disease.
X-rays of the lungs were carried out as needed by the
majority of respondents, and this frequency was largely
independent of disease state.
Other monitoring tests
The percentage of all PID patients seen regularly by a chest
physician varied widely, with answers ranging from 30 to
100%. The percentage of chest and sinus exacerbations
which did not have microbiology tests performed also var-
ied; 69% of respondents stated that 50% or more of their
patients had no microbiology tests performed.
Guidelines
Centre guidelines were followed when available. Only three
of 13 respondents, from centres in Italy and Sweden, stated
that they follow national guidelines; respondents from
centres in the United Kingdom, Germany, Spain, Belgium
and the Netherlands specifically reported a lack of national
guidelines. Guidelines followed included those from the
Immune Deficiency Foundation [17], Italian Primary
Immunodeficiency Network [18], UK Primary Immunode-
ficiency Network and additional published guidelines
[5,19–22].
Discussion
Our survey has revealed a great deal of variation across
Europe in how frequently PID patients attend clinics and
how frequently some monitoring tests are carried out in
PID patients with and without lung disease, reflecting the
lack of guidelines or standardised routines for respiratory
monitoring in patients with PID [3].
Fig. 5. Frequency with which imaging is performed in patients with
primary immunodeficiency (PID). : Performed at clinic visit;
: Performed as required; : Never performed. P 5 paediatric
patients (eight centres); A 5 adult patients (nine centres).
CT 5 computed tomography; MRI 5 magnetic resonance imaging.
Screening respiratory status in PID
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The frequency at which patients’ quality of life should be
monitored is also not standardised which was reflected in
the wide range of frequencies indicated by the survey
respondents. However, results from a self-reported survey
of 1526 patients with PID showed that recognising the fac-
tors that drive perceived health is key for delivering appro-
priate treatment to individual patients with PID [23].
These findings highlight the importance of selecting the
most appropriate methods and standardising quality of life
and perceived health assessments in PID patients.
Variation in the frequency with which some monitoring
tests were performed may be due to differences in health-
care services provided in different countries. Moreover,
international guidelines are not yet available to harmonise
disparities in monitoring between different countries. Also,
the availability of some laboratory tests, as well as access to
physiotherapy and pulmonary rehabilitation, may be influ-
enced by expertise and funding available at different
centres; these factors may also influence the frequency of
clinic visits, the availability of respiratory physicians and
the use of some monitoring protocols/tests.
As mentioned in the Introduction, some differences
existed between the frequency with which some clinical
and laboratory monitoring tests were performed in adult
versus paediatric patients, which may be due to the chal-
lenges of performing tests such as MRI, HCRT and TLCO
in very young children. Conversely, it should be noted that
other variables, such as the rate of growth and weight gain
(not investigated in this survey), form important aspects of
assessment and monitoring in children but are not an issue
in adults.
High-resolution CT scan is a valuable tool for diagnosing
and also monitoring, and can lead to early detection of
lung abnormalities. In this study, participants were in
agreement that adult patients should have a baseline
HRCT, but the exact frequency of CT evaluation for follow-
up is less well defined. Most experts suggest HRCT should
be performed every 2–4 years for patients with proven and
potentially progressive lung abnormalities and less frequent
in patients with normal lung findings, as demonstrated in
the literature [5,20,24,25]. However, its use must carefully
consider a small risk associated with the ionising radiation
exposure required for CT scans [26]. This consideration is
particularly pertinent to children; thus, although HRCT
should be considered in paediatric patients to monitor dis-
ease progression [1], it should not be used on a regular
basis in children without lung disease. The cost of CT scans
and whether the results will affect patient management
should also be considered. The expectation that imaging
studies can be used to monitor patients may be misplaced;
if there is accelerated disease progression the achievable
interval is too long, and other approaches are required to
help optimise the timing of interventions. MRI provides an
alternative to HRCT but is not yet used widely for diagno-
sis and monitoring of lung disorders in PID.
As expected, results from our survey suggested that there
is an increase in the perceived prevalence of lung disease in
adult PID patients compared to paediatric patients, which
appeared to occur despite current monitoring and treat-
ment interventions. Respondents reported that while lung
disease is seen less commonly in patients less than 10 years
old, this may depend upon the level of screening, and chil-
dren diagnosed with PID when they were older were more
likely to have already established lung disease. Differences
in the prevalence of lung disease may reflect the increased
duration of infection in the presence of poor antibody
function and of exposure to pathogens in adults, and
delayed diagnosis and/or under-treatment. In addition,
lung disease may be caused by inflammation secondary to
immune dysregulation during an extended period of time
[20], and co-morbidities including sinus disease, airflow
obstruction and gastro-oesophageal reflux disease may
influence infective exacerbation rates of bronchiectasis and
potentially disease progression. Thus, adults are more likely
to be affected than paediatric patients due to their
increased duration of exposure. Improvements in the qual-
ity of care over the last 20–30 years may also have an
impact upon the prevalence of lung disease in adult
patients. Children with PID currently receive better care
and may be less ill than those treated some time ago, who
are now the adults included in this survey. Further investi-
gation is needed to determine whether opportunities exist
to improve monitoring and treatment to prevent
progression.
The types of PID diagnosed also differed between adult
and paediatric patients. This may be due in part to the dif-
ficulty in distinguishing between transient hypogammaglo-
bulinaemia and CVID in some young children until the
immune system is sufficiently mature, with the opportu-
nity to reassess this over time. For patients with hypogam-
maglobulinaemia, subclinical infection and inflammation
represent an important concern that can lead to persistent
immune activation and chronic lung disease [3]. Some
antibody deficiency syndromes in children may resolve or
improve with age and maturation of the immune system,
especially transient hypogammaglobulinaemia of infancy
(THI) [27]; however, only a small proportion of such
patients are likely to require immunoglobulin replacement.
Large clinical studies are currently under way to assess the
impact of microbiology and virology testing, and it is
hoped that their results will inform relevant guidelines in
the near future.
Our survey has highlighted a lack of local, national and
European guidelines for screening and treating lung disease
in PID. There is a strong need for evidence-based consensus
guidelines on how to monitor and treat patients both with
no lung disease, with different types of lung disease
encountered in PID with antibody deficiencies, and in dif-
ferent age groups – especially as emerging therapeutic
modalities may be different (for example, IgG replacement
S. Jolles et al.
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therapy and antibiotics compared to corticosteroids, rituxi-
mab and other immunosuppressive therapies). Such guide-
lines will also probably need to accept that monitoring and
treatment of any lung disease that is discovered will need to
be individualised and provide guidance as to how this
should be carried out. Moreover, there are no standardised
protocols for the use of biomarkers to predict disease
course and complications, nor to record the presence or
progression of lung disease [3]. In addition, there is cur-
rently no formal tool validated or accepted specifically for
use in PID patients for the measurement of changes in
overall health, in particular the importance of evaluating
the patients’ general wellbeing, such as quality of life or
fatigue assessment. The development of formal tools or
scoring systems, such as the St George’s respiratory ques-
tionnaire or validated quantitative scales for monitoring
sinus and chest infections, could be beneficial for monitor-
ing the progression of symptoms in patients with PID.
Tools used to monitor lung disease in other settings, such
as the British Thoracic Society quality standard [28], the
Bronchiectasis Severity Index [29] or the FACED score
[30], may have utility in the setting of PID.
Current guidelines focus mainly on diagnosis over the
treatment of lung disease in PID patients. The lack of con-
sensus on assessment, and preventive and therapeutic
measures for lung disease in PID patients, may be due to
factors such as small patient cohorts, variation in the crite-
ria used for diagnosis, different aetiologies of PID and dif-
fering doses of replacement IgG. In addition, although IgG
replacement therapy reduces infections in PID patients
effectively (particularly severe infections such as pneumo-
nia) [4], the effect of different doses of IgG on chronic lung
disease, mucosal infections, bacterial colonisation pathogen
persistence, upper airway infections (especially viral infec-
tions) and inflammation is less clear.
Some important limitations of this survey should be
mentioned. First, this was not a prospective study; our
report represents a snapshot of the way patients are treated
across different centres at one point in time. As such, we
did not assess the use of diagnostic and baseline tests, such
as HRCT. Also, there is a possibility that some results could
be confounded by conditions such as autoimmune cytope-
nia, which occur more frequently in patients with lung dis-
ease. In patients with these conditions, immunosuppressive
therapy is given for reasons not related directly to lung dis-
ease, meaning that these patients are more likely to require
different therapies and may be required to attend the clinic
more often. In addition, co-morbidities which influence
the management of lung disease may differ between adults
and children.
In conclusion, our survey has shown differences in how
frequently various monitoring methods are carried out at
different European centres in PID patients with or without
lung disease. Results from this survey define current prac-
tice and highlight clearly the need for consensus guidelines
on how to monitor and treat lung complications in
patients with PID. This would allow the application of
agreed standards and the use of key performance indicators
to harmonise care and utilise these as outcome measures;
an approach that has been used successfully in the clinical
accreditation of Immunodeficiency Centres. There is also a
need for standardised biomarkers and assessment tools to
monitor disease progression, which would allow data to be
compared between centres. It is hoped that evidence from
well-planned and controlled clinical studies will allow the
development of evidence-based guidelines for monitoring
and treatment of different groups of patients with PID,
which would help to ensure that all PID patients receive
optimal care.
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